Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
ATR safeguards epithelial-to-mesenchymal transition by countering R-loops and enabling transcription reprogramming
Parasvi S. Patel, Jacob P. Matson, Xiaojuan Ran, Marcello Stanzione, Ajinkya S. Kawale, Mingchao Wang, Sneha Saxena, Conrad Sander, Jacquelyn Curtis, Jessica L. Hopkins, Edmond Wong, Ryan B. Corcoran, Daniel A. Haber, Nicholas J. Dyson, Shyamala Maheswaran, Lee Zou
Parasvi S. Patel, Jacob P. Matson, Xiaojuan Ran, Marcello Stanzione, Ajinkya S. Kawale, Mingchao Wang, Sneha Saxena, Conrad Sander, Jacquelyn Curtis, Jessica L. Hopkins, Edmond Wong, Ryan B. Corcoran, Daniel A. Haber, Nicholas J. Dyson, Shyamala Maheswaran, Lee Zou
View: Text | PDF
Research Article Cell biology Oncology

ATR safeguards epithelial-to-mesenchymal transition by countering R-loops and enabling transcription reprogramming

  • Text
  • PDF
Abstract

Transitions of cancer cells between distinct cell states, which are typically driven by transcription reprogramming, fuel tumor plasticity, metastasis, and therapeutic resistance. Whether the transitions between cell states can be therapeutically targeted remains unknown. Here, using the epithelial-to-mesenchymal transition (EMT) as a model, we show that the transcription reprogramming during a cell-state transition induces genomic instability through R-loops and transcription-replication conflicts and that the cell-state transition cannot occur without the ATR kinase, a key regulator of the replication stress response. ATR inhibition during EMT not only increased transcription- and replication-dependent genomic instability, but also disrupted transcription reprogramming. Unexpectedly, ATR inhibition elevated R-loop–associated DNA damage at the SNAI1 gene, a key driver of the transcription reprogramming during EMT, triggering ATM- and Polycomb-mediated transcription repression of SNAI1. Beyond SNAI1, ATR also suppressed R-loops and antagonized repressive chromatin at a subset of EMT genes. Importantly, inhibition of ATR in tumors undergoing EMT reduced tumor growth and metastasis, suggesting that ATR inhibition eliminates cancer cells in transition. Thus, during EMT, ATR not only protects genome integrity but also enables transcription reprogramming, revealing that ATR is a safeguard of cell-state transitions and a target to suppress tumor plasticity.

Authors

Parasvi S. Patel, Jacob P. Matson, Xiaojuan Ran, Marcello Stanzione, Ajinkya S. Kawale, Mingchao Wang, Sneha Saxena, Conrad Sander, Jacquelyn Curtis, Jessica L. Hopkins, Edmond Wong, Ryan B. Corcoran, Daniel A. Haber, Nicholas J. Dyson, Shyamala Maheswaran, Lee Zou

×

Figure 4

ATR enables SNAI1 expression during EMT.

Options: View larger image (or click on image) Download as PowerPoint
ATR enables SNAI1 expression during EMT.
(A) Western blot of SNAI1 in in...
(A) Western blot of SNAI1 in indicated cells treated with TGF-β and various ATRis (10 μM) at indicated time points. (B) Bar graph showing SNAI1 mRNA in the indicated cell populations. (C) Schematic of SNAI1 indicating primer location for CUT&RUN qPCR and DRIP-qPCR. (D) Heatmap showing average H2AK119ub1 enrichment via CUT&RUN qPCR at various SNAI1 loci shown in C in MCF10A cells. (E) Heatmap of average γH2AX enrichment via CUT&RUN treated and quantified as in D. (F) Heatmap of average S9.6 enrichment via DRIP-qPCR at various SNAI1 loci in MCF10A cells. Mean signal normalized to input for each condition and then to DMSO. (G) Heatmap showing average S9.6 enrichment via DRIP-qPCR at various SNAI1 loci in indicated cells. (H) Heatmap showing average γH2AX (left) and H2AK119ub1 (right) enrichment via CUT&RUN qPCR at various SNAI1 loci in the indicated cell populations treated with TGF-β and AZD6738 and/or 10 μM ATMi KU55933. (I) Bar graph showing SNAI1 mRNA in the indicated MCF10A cell populations. (J) Western blot of the indicated proteins in MCF10A cells treated with TGF-β and AZD6738 and/or 10 μM ATMi KU55933 for 24 h. (K) Bar graph showing SNAI1 mRNA in MCF10A cells treated TGF-β and AZD6738 and/or indicated EZH2 inhibitors (10 μM). (L) Schematic of proposed model. Statistical significance was determined using 1-way ANOVA for B, I, and K. Three to six biological replicates were performed for each experiment. Doxycycline (50 ng/mL) was used to induce RNaseH1 for 24 h prior to treatment. The 5′ pause region of ACTB was used as a control. For experiments in B–K, cells were treated for 24 h with 5 ng/mL TGF-β and 1 μM AZD6738. P values are indicated in the figure.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts